Artículos Científicos

  1. Warner, S. Diagnostics + Therapy = Theranostics. Strategy requires teamwork, partnering, and tricky regulatory maneuvering. The Scientist 18 (16): 38. (2004).
  2. Dancey, J.E. et al. The Genetic Basis for Cancer Treatment Decisions. Cell 148: 409-420 (2012).
  3. Beadling C. et al. Multiplex Mutation Screening by Mass Spectrometry: Evaluation of 820 Cases from a Personalized Cancer Medicine Registry. The Journal of Molecular Diagnostics 13 (5): 504-513. (2011).
  4. Sharma SV, et al. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 10(4):241-53. (2010).
  5. Thomas RK, et al. High-throughput oncogene mutation profiling in human cancer. Nat Gen 39 (3): 347-351. (2007).
  6. Chen-Hsiang Yeang, et al. Combinatorial patterns of somatic gene mutations in cancer. The FASEB Journal 22: 2605-2622. (2008).
  7. Pao W. The VICC Personalized Cancer Medicine Initiative. Review Symposium. Vanderbilt-Ingram Cancer Center 8th Annual Oncology & Hematology. (2011).
  8. MacConaill, L.E et al. Clinical Implications of the Cancer Genome. Journal of Clinical Oncology 28 (35): 5219 – 5228. (2010).
  9. Corless C. Semiconductor-based Sequencing for Cancer Diagnostics: Gamblig with Chips. Association of Molecular Pathology annual meeting 2011. [online] Pincha aquí
  10. Li M. Next Generation Cancer Gene Sequencing for Clinically Actionable Mutations. Association of Molecular Pathology annual meeting 2011. [online] Pincha aquí
  11. Li M. The Efficacy of Next Generation Sequencing for Detection of Clinically Actionable Mutations in Cancer. Advances in Genome Biology and Technology 2012. [online] Pincha aquí
  12. Stratton, MR, et al. The cancer genome. Nature 458 (7239): 719. (2009).
  13. MacConaill, L.E et al. Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples. Plos One 4 (11): e7887 (2009).
  14. La Thangue, N. B. et al. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol. 8, 587–596 (2011)
  15. Wong, K.M., et al. Unraveling the genetics of cancer: Genome Sequencing and Beyond. Annu. Rev. Genomics Hum. Genet. 12: 407-30 (2011)
  16. National Cancer Institute. Targeted Cancer Therapies [online] Pincha aquí (2012).
  17. Jackson D. et al. Personalized cancer medicine—advances and socio-economic challenges. Nature Reviews Clinical Oncology 8, 735-741(2011).
  18. Ross, J.S. et al. Whole cancer genome sequencing by Next-Generation Methods. Am. J. Clin. Pathol. 136: 527-539 (2011).
  19. Leary R.J. et al. Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing. Sci Transl Med. 2 (20): 20ra14. (2010).
  20. Strausberg R.L. et al. Whole-genome cancer analysis as an approach to deeper understanding of tumor biology. British Journal of Cancer 102: 243-248 (2010).
  21. Taylor B.S. et al. Clinical cancer genomics: how soon is now? J Pathol 223: 318-326 (2011).
  22. Vogenberg F.R. et al. Personalized Medicine. Part I: Evolution and Development into Theranostics. P&T 35 (10). (2010).
  23. McDermott U. et al. High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor. Methods Enzymol.438:331-41. (2008)
  24. Shen Yang, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood, American Society of Hematology 118 (20): 5593-5603. (2011).
  25. McDermott U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 104(50):19936-41. (2007).
  26. Jänne PA. et al. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov. 8(9):709-23. Review. (2009).
  27. J. van ’t Veer L, et al. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452 (3): 564-570. (2008).
  28. Dias-Santagata, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine EMBO Molecular Medicine 2 (5): 146–158. (2010).
  29. The International Cancer Genome Consortium. International network of cancer genome projects. Nature 464 (7291): 993–998. (2010).
  30. Barretina J. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-307. (2012).
  31. Mathew J. et. al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575. (2012)